Department of Nursing, Nanfang Hospital, Southern Medical University, Guangzhou, China,
School of Nursing, Southern Medical University, Guangzhou, China,
Oncol Res Treat. 2021;44(5):252-260. doi: 10.1159/000515756. Epub 2021 Apr 28.
Breast cancer is the most frequently diagnosed cancer among women and ranks second in terms of global incidence. Depression, anxiety, and poor quality of life (QoL) are prevalent in women with breast cancer. Supportive-expressive group therapy (SEGT) can potentially benefit these patients.
This systematic review and meta-analysis evaluated the effectiveness of SEGT for women with breast cancer, by focusing on survival, QoL, anxiety, and depression as outcomes.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were adopted. The databases PubMed, Web of Science, Cochrane Library, Embase, CINHAL, and PsycInfo in English, and Sinomed, CNKI, CQVIP, and Wanfang in Chinese, were searched from inception up to May 2020 for relevant full-text articles using "SEGT," "breast cancer," and related terms as keywords. Randomized controlled trials (RCTs) comparing SEGT with baseline conditions of patients with breast cancer were included in the analysis.
Ten studies with a total of 2,879 subjects were analyzed. Overall group differences were found for survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.72-0.94; p = 0.004), short-term QoL (mean difference [MD] 8.02, 95% CI 4.85-11.20; p < 0.00001), long-term QoL (MD 11.30, 95% CI 6.75-15.84; p < 0.00001), Profile of Mood States score (POMS) score (MD -0.43, 95% CI -0.72 to -0.13; p = 0.005), anxiety (standardized MD [SMD] -0.30, 95% CI -0.49 to -0.10; p = 0.003), and depression (SMD -0.47, 95% CI -0.66 to -0.29; p < 0.00001).
SEGT is effective in improving QoL and psychosocial status in breast cancer patients, but there is no convincing evidence that it has an impact on survival.
乳腺癌是女性最常见的癌症，也是全球发病率第二高的癌症。患有乳腺癌的女性普遍存在抑郁、焦虑和生活质量（QoL）差的问题。支持性表达团体治疗（SEGT）可能对这些患者有益。
本系统评价和荟萃分析通过关注生存、QoL、焦虑和抑郁等结果，评估了 SEGT 对乳腺癌女性的有效性。
采用系统评价和荟萃分析的首选报告项目指南。使用“SEGT”、“乳腺癌”和相关术语作为关键字，在英文数据库 PubMed、Web of Science、Cochrane Library、Embase、CINHAL 和 PsycInfo 以及中文数据库 Sinomed、CNKI、CQVIP 和万方中搜索从开始到 2020 年 5 月的相关全文文章，以纳入分析比较 SEGT 与乳腺癌患者基线条件的随机对照试验（RCT）。
分析了 10 项共 2879 名受试者的研究。总体组间差异在生存方面有发现（风险比 [HR] 0.82，95%置信区间 [CI] 0.72-0.94；p = 0.004），短期 QoL（平均差异 [MD] 8.02，95% CI 4.85-11.20；p < 0.00001），长期 QoL（MD 11.30，95% CI 6.75-15.84；p < 0.00001），心境状态问卷（POMS）评分（MD -0.43，95% CI -0.72 至 -0.13；p = 0.005），焦虑（标准化 MD [SMD] -0.30，95% CI -0.49 至 -0.10；p = 0.003）和抑郁（SMD -0.47，95% CI -0.66 至 -0.29；p < 0.00001）。
SEGT 可有效改善乳腺癌患者的 QoL 和心理社会状况，但尚无令人信服的证据表明其对生存有影响。
